Market Overview:

The global single-use bioreactors market reached a value of US$ 2.54 Billion in 2021. Looking forward, IMARC Group expects the market to reach a value of US$ 6.23 Billion by 2027, exhibiting a CAGR of 15.50% during 2022-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.

A single-use bioreactor (SUB), also known as a disposable bioreactor, relies on a disposable bag instead of a culture vessel made using stainless steel or glass. It is flexible and easy to use and install, and requires fewer utility requirements, including steam and water. Besides this, it reduces labor costs, minimizes the risk of cross-contamination, and eliminates the cleaning process and validation issue. As a result, it finds extensive applications in contract research organizations (CROs) and contract manufacturing organizations (CMOs) worldwide.

Single-Use Bioreactors Market Trends:

SUBs are employed in the pharmaceutical industry for media and buffer preparation, cell harvesting, filtration, purification, and virus inactivation. They are also used in academic and commercial-scale laboratories for drug discovery, biofuel manufacturing, and the development of vaccines and antibodies. This, in confluence with the burgeoning biopharmaceutical industry, represents one of the key factors impelling the growth of the market. Moreover, autoclaving a conventional bioreactor can become a lengthy, costly, and inconsistent pharmaceutical manufacturing process. However, SUBs utilize presterilized bioprocess bags and consequently reduce the additional costs and time of sterilization. Besides this, as they have fewer moving parts than conventional bioreactors, SUBs are less expensive to maintain. Apart from this, SUBs have a lower overall impact on the environment compared to stainless steel equipment. This, coupled with the growing number of clinical trials around the world, is catalyzing their demand across the globe. Furthermore, leading players are increasingly focusing on product innovations and mergers and acquisitions (M&A) to expand their customer base and increase their geographical presence. This, along with the rising adoption of single-use technology (SUT), is augmenting the overall sales and profitability.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global single-use bioreactors market, along with forecasts at the global, regional and country level from 2022-2027. Our report has categorized the market based on product type, type, cell type, molecule type and end user.

Breakup by Product Type:

• Single-use Bioreactor Systems
• Media Bags
• Filtration Assemblies
• Others
   

Breakup by Type:

• Stirred-tank Bioreactors
• Wave-induced Bioreactors
• Bubble-column Bioreactors
• Others
   

Breakup by Cell Type:

• Mammalian Cell
• Bacteria
• Yeast
• Others
   

Breakup by Molecule Type:

• Vaccines
• Monoclonal Antibodies
• Stem Cells
• Recombinant Proteins
• Others
   

Breakup by End User:

• Pharmaceutical and Biopharmaceutical Companies
• Contract Research Organizations
• Academic and Research Institutes
• Others
   

Breakup by Region:

• North America
  • United States
  • Canada
• Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
• Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
• Latin America
  • Brazil
  • Mexico
  • Others
• Middle East and Africa
   

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being ABEC Inc., Cellexus, Celltainer Biotech B.V., CESCO Bioengineering Co. Ltd., Distek Inc., Eppendorf SE, General Electric Company, Getinge AB, Merck KGaA, Pall Corporation (Danaher Corporation), PBS Biotech Inc., Sartorius AG and Thermo Fisher Scientific Inc.

Report Coverage: